Status:

RECRUITING

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab)

Lead Sponsor:

Amgen

Conditions:

Relapsing-remitting Multiple Sclerosis (RRMS)

Eligibility:

All Genders

18-99 years

Phase:

PHASE3

Brief Summary

The main objectives of the study are to demonstrate pharmacokinetics (PK) similarity between ABP 692 and Ocrelizumab (US), and ABP 692 and Ocrelizumab (EU), and to demonstrate pharmacodynamics (PD) si...

Eligibility Criteria

Inclusion

  • Diagnosis of RRMS in accordance with the revised McDonald Criteria 2017 (Thompson et al, 2018).
  • Expanded Disability Status Scale score at screening ≥ 0 and ≤ 5.5 inclusive.
  • Evidence of recent MS activity as defined by the study protocol.
  • Neurologically stable subject, with no relapse for ≤ 28 days before randomization.

Exclusion

  • Diagnosis of primary progressive or with secondary progressive MS (Thompson et al, 2018).
  • Multiple sclerosis disease duration of ≥ 10 years in Participants with Expanded Disability Status Scale (EDSS) score of ≤ 2.5 at screening.
  • Any contraindications to study procedures or medications as outlined in the study protocol.
  • Any prohibited medication as defined in the study protocol.
  • Any significant concomitant disease that may require chronic treatment with systemic corticosteroids and/or systemic immunosuppressants during the study.
  • Current or history of any significant medical conditions as described in the study protocol.
  • Any abnormal laboratory blood values as defined in the study protocol.

Key Trial Info

Start Date :

January 13 2025

Trial Type :

INTERVENTIONAL

Allocation :

ESTIMATED

End Date :

December 17 2027

Estimated Enrollment :

444 Patients enrolled

Trial Details

Trial ID

NCT06700343

Start Date

January 13 2025

End Date

December 17 2027

Last Update

March 6 2026

Active Locations (105)

Enter a location and click search to find clinical trials sorted by distance.

Page 1 of 27 (105 locations)

1

University of South Alabama

Mobile, Alabama, United States, 36617

2

Clinical Endpoints, LLC

Scottsdale, Arizona, United States, 85258

3

Profound Research - Neurology Center of Southern California

Carlsbad, California, United States, 92011

4

Mountain Neurological Research Center

Basalt, Colorado, United States, 81621

Comparison Between ABP 692 and Ocrevus® (Ocrelizumab) | DecenTrialz